Strict NPO status for at least 8 hours. Comprehensive physical examination and anesthesia clearance. Optimization of systemic comorbidities, including glycemic control. Administration of weight-based prophylactic systemic antibiotics. Obtain baseline inflammatory markers (ESR, CRP). Sterile site marking and preoperative skin preparation.
Monitor for signs of systemic infection or wound complications. Initiate intravenous antibiotic therapy based on intraoperative culture results. Implement a physical therapy program for range of motion, as permitted by the spacer configuration. Manage pain with multimodal analgesia. Discharge upon clinical stability with long-term antibiotic plan and follow-up for Stage 2 revision.
Comprehensive Clinical Guide: Spacer Placement for Infected Arthroplasty
1. Introduction & Overview
Periprosthetic joint infection (PJI) remains one of the most devastating complications following total joint arthroplasty (TJA). When a PJI is diagnosed, the definitive treatment typically involves a two-stage exchange arthroplasty. A critical component of this surgical strategy is the placement of an antibiotic-loaded spacer.
The spacer serves as a temporary implant designed to maintain joint space, preserve soft tissue tension, and deliver high local concentrations of antibiotics to the infected site while the systemic infection is cleared. This guide provides an exhaustive clinical overview of the spacer placement procedure, its mechanisms, and the associated perioperative management.
2. Technical Specifications & Mechanisms
The spacer is not merely a structural placeholder; it is a sophisticated drug-delivery system.
The Biomechanical Role
- Maintenance of Joint Space: Prevents the collapse of soft tissues and contracture of the capsule and ligaments.
- Limb Alignment: Maintains appropriate limb length to facilitate easier revision surgery.
- Soft Tissue Preservation: Prevents scarring and fibrosis that would otherwise make a secondary total joint replacement technically impossible.
The Pharmacological Role
The spacer acts as a localized antibiotic reservoir. By incorporating heat-stable antibiotics (e.g., Vancomycin, Tobramycin, Gentamicin) into polymethylmethacrylate (PMMA) bone cement, the surgeon achieves local concentrations significantly higher than those achievable via intravenous administration, without the associated systemic toxicity.
| Feature | Static Spacers | Articulating Spacers |
|---|---|---|
| Mobility | None (Fixed) | Allows for joint range of motion |
| Soft Tissue | Higher risk of contracture | Better preservation of motion |
| Bone Loss | Easier to use in massive defects | Requires some bone stock |
| Complexity | Low | High |
3. Clinical Indications & Usage
Spacer placement is indicated primarily for the management of chronic, deep-seated periprosthetic joint infections.
Indications
- Confirmed PJI: Based on MSIS (Musculoskeletal Infection Society) criteria.
- Unstable Infection: Failure of debridement, antibiotics, and implant retention (DAIR).
- Significant Bone Loss: When structural support is needed to bridge gaps during the interval between stages.
- Severe Soft Tissue Compromise: Where the risk of joint stiffness is high.
Contraindications
- Systemic Sepsis: Patient must be hemodynamically stable before undergoing major orthopedic surgery.
- Severe Immunocompromise: Where the patient cannot mount an immune response to clear the infection.
- Poor Vascularity: Inadequate soft tissue coverage or compromised arterial supply (relative contraindication).
4. The Surgical Procedure: A Step-by-Step Approach
Phase I: Debridement (The "First Stage")
- Excision: Complete removal of all components (femoral, acetabular, or tibial) and all cemented or porous-coated implants.
- Aggressive Debridement: Synovectomy and removal of all necrotic tissue, pseudomembrane, and fibrin.
- Irrigation: Pulsatile lavage with large volumes of saline (minimum 6–9 liters).
- Tissue Sampling: Multiple deep tissue cultures (minimum 5–6) are obtained to identify the causative organism.
Phase II: Spacer Fabrication & Implantation
- Cement Mixing: PMMA is mixed with high-dose, heat-stable antibiotics.
- Molding: Using either manual molding or pre-formed molds, the cement is shaped to mimic the anatomy of the joint.
- Insertion: The spacer is placed into the joint space. For articulating spacers, the interface between the cement and the bone/cartilage is often reinforced with cement to ensure stability.
- Closure: Layered closure, often with the placement of closed-suction drains.
5. Post-Operative Recovery & Management
The recovery period following spacer placement is structured around the "antibiotic holiday" and the monitoring of inflammatory markers.
- Antibiotic Therapy: Patients typically receive 6 weeks of targeted intravenous or oral antibiotics based on culture results.
- Monitoring Markers: Serial ESR (Erythrocyte Sedimentation Rate) and CRP (C-Reactive Protein) levels are monitored to track the resolution of the infection.
- Physical Therapy: If an articulating spacer is used, early range-of-motion exercises are encouraged to prevent stiffness. If a static spacer is used, the limb is typically immobilized.
- Re-implantation Criteria: The second stage is generally considered only when:
- Systemic inflammatory markers have normalized.
- Wound is completely healed without drainage.
- Cultures from a pre-reimplantation aspiration (if performed) are negative.
6. Risks and Potential Complications
While spacer placement is life-saving and joint-saving, it carries inherent risks:
- Spacer Fracture: Common in static or poorly manufactured spacers; can lead to bone damage.
- Dislocation: Particularly in hip spacers; the lack of a proper locking mechanism makes them prone to instability.
- Persistent Infection: If the debridement was incomplete or the organism is resistant to the chosen antibiotics.
- Bone Loss: The spacer can cause osteolysis if it is loose or creates micro-motion against the host bone.
- Systemic Toxicity: While rare, leaching of high-dose antibiotics can occasionally cause renal or ototoxicity.
7. FAQ: Frequently Asked Questions
Q1: How long can a spacer stay in the body?
A: Typically, spacers are kept for 6 to 12 weeks. However, in cases of difficult-to-treat organisms, they may remain for 6 months or longer.
Q2: Is a spacer considered a permanent implant?
A: No. It is a temporary device and must be removed during the second stage of surgery.
Q3: Can I walk on a spacer?
A: This depends on the surgeon and the type of spacer. Generally, patients are advised to be non-weight-bearing or toe-touch weight-bearing to prevent spacer breakage.
Q4: How do we choose the right antibiotic for the cement?
A: We use "heat-stable" antibiotics like Vancomycin, Gentamicin, or Tobramycin. The choice is determined by the specific bacteria isolated from the preoperative aspiration or intraoperative cultures.
Q5: What happens if the infection does not clear?
A: Options include prolonged antibiotic suppression, resection arthroplasty (Girdlestone procedure for hips), or permanent arthrodesis (fusion).
Q6: Are there alternatives to spacer placement?
A: Yes, DAIR (Debridement, Antibiotics, and Implant Retention) is an option for acute infections. For chronic infections, there are no viable alternatives to removing the infected hardware.
Q7: Will my joint function be normal with a spacer?
A: No. A spacer is designed for infection control, not functional performance. You will have significant limitations in range of motion and strength.
Q8: Does the spacer release antibiotics forever?
A: Most of the antibiotic is released within the first 48–72 hours. The elution then drops off significantly, which is why systemic antibiotics are still required.
Q9: What is a "static" vs. "articulating" spacer?
A: A static spacer is a solid block of cement. An articulating spacer is designed to move, allowing the patient to maintain some joint function during the treatment period.
Q10: What are the success rates of two-stage exchange?
A: Success rates for clearing the infection range from 85% to 95%, depending on the organism, host factors, and surgical technique.
8. Alternative Treatments & Future Directions
While the two-stage exchange with spacer placement remains the "Gold Standard," other approaches are evolving:
- Single-Stage Exchange: Replacing the infected components with new ones in a single surgery. This is reserved for patients with known, sensitive organisms and minimal bone loss.
- Long-term Antibiotic Suppression: Used for patients who are too frail to undergo further surgery.
- Resection Arthroplasty: Removal of the implant without replacement, leading to a "flail" joint; reserved for patients with severe, recurrent, or incurable infections.
- 3D Printed Spacers: Emerging technology allows for patient-specific spacers that provide better fit and stability than manual molds.
Conclusion
The management of infected arthroplasty via spacer placement is a complex, multi-disciplinary process. By prioritizing thorough surgical debridement, precise antibiotic elution from the PMMA spacer, and rigorous postoperative monitoring, orthopedic surgeons can successfully eradicate infection and provide the foundation for a successful second-stage reconstruction. Patients should be counseled that this is a marathon, not a sprint, requiring patience and adherence to the prescribed rehabilitation protocol.
Disclaimer: This guide is for educational and clinical reference purposes only. It does not replace the professional judgment of a board-certified orthopedic surgeon. Clinical decisions must always be tailored to the individual patient’s comorbidities, local facility protocols, and specific microbiological data.